Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1636-1647

  Kudo, Hideo ^a   Jinnin, Masatoshi ^a   Asano, Yoshihide ^b   Trojanowska, Maria ^c   Nakayama, Wakana ^a   Inoue, Kuniko ^a   Honda, Noritoshi ^a   Kajihara, Ikko ^a   Makino, Katsunari ^a   Fukushima, Satoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1 ALPHA 2; ENDOGLIN; INTERLEUKIN 20; INTERLEUKIN 20 RECEPTOR; INTERLEUKIN RECEPTOR; MESSENGER RNA; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; REGULATORY MECHANISM; SCLERODERMA; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; BLEOMYCIN; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PHENOTYPE; RECEPTORS, CELL SURFACE; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SIGNAL TRANSDUCTION; SKIN; SMAD3 PROTEIN;

EID: 84901609119     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38380     Document Type: Article

References (48)

1. Uitto J, Kouba D,. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 2000; 24: 60-9.
2. Trojanowska M, LeRoy EC, Eckes B, Krieg T,. Pathogenesis of fibrosis: type I collagen and the skin. J Mol Med (Berl) 1998; 76: 266-74.
3. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
4. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
5. Ihn H, Yamane K, Kubo M, Tamaki K,. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001; 44: 474-80.
6. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K,. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
7. Takehara K,. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 2003; 30: 755-9.
8. Overbeek MJ, Boonstra A, Voskuyl AE, Vonk MC, Vonk-Noordegraaf A, van Berkel MP, et al. Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. Arthritis Res Ther 2011; 13: R61.
9. Brissett M, Veraldi KL, Pilewski JM, Medsger TA Jr, Feghali-Bostwick CA,. Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum 2012; 64: 272-80.
10. Kawaguchi Y,. IL-1α gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clin Exp Immunol 1994; 97: 445-50.
11. Feghali CA, Bost KL, Boulware DW, Levy LS,. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19: 1207-11.
12. Makino T, Fukushima S, Wakasugi S, Ihn H,. Decreased serum IL-7 levels in patients with systemic sclerosis. Clin Exp Rheumatol 2009; 27: 68-9.
13. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104: 9-19.
14. Wegenka UM,. IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev 2010; 21: 353-63.
15. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, et al. Cloning, expression and initial characterisation of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1: 442-50.
16. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS,. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α. J Immunol 2002; 169: 4288-97.
17. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB,. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11: 2477-86.
18. Hsu YH, Li HH, Hsieh MY, Liu MF, Huang KY, Chin LS, et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006; 54: 2722-33.
19. Li HH, Cheng HH, Sun KH, Wei CC, Li CF, Chen WC, et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol 2008; 129: 277-85.
20. Wei CC, Chang MS,. A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis. Genes Immun 2008; 9: 668-79.
21. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178: 2229-40.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
23. Maricq HR, McGregor AR, Diat F, Smith EA, Maxwell DB, LeRoy EC, et al. Major clinical diagnoses found among patients with Raynaud phenomenon from the general population. J Rheumatol 1990; 17: 1171-6.
24. Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998-1006.
25. Ihn H, Sato S, Tamaki T, Soma Y, Tsuchida T, Ishibashi Y, et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992; 284: 391-5.
26. Honda N, Jinnin M, Kira-Etoh T, Makino K, Kajihara I, Makino T, et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3. Am J Pathol 2013; 182: 206-16.
27. Jinnin M, Makino T, Kajihara I, Honda N, Makino K, Ogata A, et al. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Br J Dermatol 2010; 162: 751-8.
28. Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T, et al. Constitutive activation of c-Abl/protein kinase C-δ/Fli1 pathway in dermal fibroblasts derived from patients with localized scleroderma. Br J Dermatol 2012; 167: 1098-105.
29. Asano Y, Trojanowska M,. Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 2009; 29: 1882-94.
30. Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M,. Transcriptional regulation of the human α2(I) collagen gene: combined action of upstream stimulatory and inhibitory cis-acting elements. J Biol Chem 1996; 271: 26717-23.
31. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ,. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002; 277: 21730-9.
32. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39: 3570-81.
33. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
34. Tanaka C, Fujimoto M, Hamaguchi Y, Sato S, Takehara K, Hasegawa M,. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis Rheum 2010; 62: 1723-32.
35. Marotta M, Martino G,. Sensitive spectrophotometric method for the quantitative estimation of collagen. Anal Biochem 1985; 150: 86-90.
36. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M,. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276: 20839-48.
37. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M,. Ets1 is an effector of the transforming growth factor β (TGF-β) signaling pathway and an antagonist of the profibrotic effects of TGF-β. J Biol Chem 2002; 277: 20399-408.
38. Jinnin M, Ihn H, Yamane K, Mimura Y, Asano Y, Tamaki K,. α2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res 2005; 33: 1337-51.
39. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K,. Phosphatidylinositol 3-kinase is involved in α2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 2004; 172: 7123-35.
40. Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P, et al. Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 2011; 226: 3340-8.
41. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
42. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
43. Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, Chang MS,. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006; 7: 234-42.
44. Heuze-Vourc'h N, Liu M, Dalwadi H, Baratelli FE, Zhu L, Goodglick L, et al. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun 2005; 333: 470-5.
45. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M,. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29: 425-34.
46. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48: 2256-61.
47. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
48. Haustein UF,. Systemic sclerosis-scleroderma. Dermatol Online J 2002; 8: 3.